What Next for Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Stock After Increase in Shorted Shares?

June 18, 2018 - By Marry Poplack

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Logo

The stock of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) registered an increase of 11.09% in short interest. ANTH’s total short interest was 2.14 million shares in June as published by FINRA. Its up 11.09% from 1.92M shares, reported previously. With 770,900 shares average volume, it will take short sellers 3 days to cover their ANTH’s short positions.

The stock decreased 4.87% or $0.015 during the last trading session, reaching $0.2931. About 600,775 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 86.78% since June 18, 2017 and is downtrending. It has underperformed by 99.35% the S&P500.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $7.67 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

Among 3 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Anthera Pharmaceuticals had 5 analyst reports since January 22, 2018 according to SRatingsIntel. Jefferies maintained the stock with “Hold” rating in Tuesday, March 6 report. The stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) earned “Sell” rating by Piper Jaffray on Monday, March 12. The company was maintained on Tuesday, February 13 by Jefferies. The stock has “Buy” rating by Piper Jaffray on Monday, January 22.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: